Evidence map›Paper›PMID 38328306›Full record

ArticleFrontiers in cell and developmental biology2023

Exploring the tumor micro-environment in primary and metastatic tumors of different ovarian cancer histotypes.

Bingqing Xie, Susan Olalekan, Rebecca Back, Naa Asheley Ashitey, Heather Eckart, Anindita Basu

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bingqing XieSection of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, United States.
Susan OlalekanSection of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, United States.
Rebecca BackSection of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, United States.
Naa Asheley AshiteySection of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, United States.
Heather EckartSection of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, United States.
Anindita BasuSection of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is a highly heterogeneous disease consisting of at least five different histological subtypes with varying clinical features, cells of origin, molecular composition, risk factors, and treatments. While most single-cell studies have focused on High grade serous ovarian cancer, a comprehensive landscape of the constituent cell types and their interactions within the tumor microenvironment are yet to be established in the different ovarian cancer histotypes. Further characterization of tumor progression, metastasis, and various histotypes are also needed to connect molecular signatures to pathological grading for personalized diagnosis and tailored treatment. In this study, we leveraged high-resolution single-cell RNA sequencing technology to elucidate the cellular compositions on 21 solid tumor samples collected from 12 patients with six ovarian cancer histotypes and both primary (ovaries) and metastatic (omentum, rectum) sites. The diverse collection allowed us to deconstruct the histotypes and tumor site-specific expression patterns of cells in the tumor, and identify key marker genes and ligand-receptor pairs that are active in the ovarian tumor microenvironment. Our findings can be used in improving precision disease stratification and optimizing treatment options.

Indexed as

cancer associated fibroblastscell type annotationligand-receptor analysismetastatic tumor siteovarian cancer histotypesprimary tumor sitesingle-cell tumor profilingtumor micro-environment

Identifiers

PMID38328306
PMCPMC10847324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.